<DOC>
	<DOCNO>NCT00855660</DOCNO>
	<brief_summary>Investigation effect Riociguat , administer 2.5 mg IR-tablets TID 14 day , bone metabolism .</brief_summary>
	<brief_title>Effect Riociguat Bone Metabolism</brief_title>
	<detailed_description>Clinical pharmacology</detailed_description>
	<criteria>Healthy male white subject 18 45 year age BMI 18 28 kg/m2 Subjects able understand follow instruction able participate study entire period Relevant deviation normal range clinical examination ; clinical chemistry , hematology , urinalysis Resting heart rate awake subject 45 BPM 90 BPM Systolic blood pressure 100 mmHg 145 mmHg Diastolic blood pressure 95 mmHg Relevant pathological change ECG second thirddegree AV block , prolongation QRS complex 120 msec QT / QTcinterval 450 msec male History genetic muscle bone disease kind Completely sedentary extremely fit subject Fractures precede 12 month Psychiatric disease History peptic ulcer relevant gastroesophageal reflux disease Subjects hypersensitivity investigational drug riociguat ranitidine , inactive constituent Regular daily consumption half liter usual beer equivalent quantity approximately 20 g alcohol another form , 1 L xanthinecontaining beverage , recent smoke history Use medication within 2 week precede study could interfere investigational drug riociguat ranitidine Subjects medical disorder , condition history would impair subject 's ability participate complete study opinion investigator sponsor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bone Metabolism</keyword>
</DOC>